Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mercaptopurine
Drug ID BADD_D01392
Description An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indications and Usage For remission induction and maintenance therapy of acute lymphatic leukemia.
Marketing Status approved
ATC Code L01BB02
DrugBank ID DB01033
KEGG ID D00161; D04931
MeSH ID D015122
PubChem ID 667490
TTD Drug ID D09UZO
NDC Product Code 62991-2899; 69076-913; 15308-0712; 12780-0299; 0054-4581; 0378-3547
UNII E7WED276I5
Synonyms Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous
Chemical Information
Molecular Formula C5H4N4S
CAS Registry Number 50-44-2
SMILES C1=NC2=C(N1)C(=S)N=CN2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.004--Not Available
Adverse drug reaction08.06.01.0090.011138%Not Available
Disease recurrence08.01.03.0500.002290%Not Available
Drug intolerance08.06.01.0130.002082%Not Available
Obstruction08.01.03.023--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.001041%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal mass20.01.02.0070.001041%Not Available
Unevaluable event08.01.03.0510.001041%Not Available
Poor quality sleep19.02.05.005; 17.15.04.002--Not Available
Gastrointestinal inflammation07.08.03.007--Not Available
Infusion site extravasation12.07.05.008; 08.02.05.007--
Bone marrow failure01.03.03.0050.008535%
Injection site papule23.03.03.045; 12.07.03.031; 08.02.03.031--Not Available
Cytopenia01.03.03.0120.001561%Not Available
Treatment failure08.06.01.017--Not Available
Hepatosplenic T-cell lymphoma16.17.01.001; 01.11.01.0010.004164%Not Available
Liver injury09.01.07.022; 12.01.17.012--Not Available
Oral disorder07.05.01.005--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Drug-induced liver injury09.01.07.023; 12.03.01.0440.005933%Not Available
Candida infection11.03.03.021--
Faeces soft07.01.03.008--Not Available
Stenosis08.01.03.060--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001041%
Central nervous system lymphoma18.04.04.013; 17.02.10.028; 16.20.01.005; 01.12.01.0050.001041%Not Available
Ileal stenosis07.13.06.0060.001041%
Rectal stenosis07.13.05.0030.001041%
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene